Summary: The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Clinical Consortium Award (CCA) provides support to develop, maintain, and enhance the necessary collaborations and resources to rapidly execute phase 2 and/or phase 2-linked phase 1 (phase1/2) prostate cancer clinical trials. The primary intent of the PCRP Clinical Consortium Award is to combine the efforts of leading investigators across multiple institutions to expedite the clinical advancement of novel therapeutic interventions in prostate cancer to decrease the impact of the disease.
Distinctive Features:
• This award mechanism does not support the development of clinical protocols.
• Coordinating Center: This award mechanism supports one coordinating center, which will be responsible for development and maintenance of the consortium organizational structure, and also function as a Clinical Research Site.
• Clinical Research Sites: This award mechanism supports multiple clinical research sites, which will be responsible for clinical trial introduction and selection, patient accrual for consortium studies, data collection and timely submissions, meeting attendance, and adherence to the consortium’s operating procedures.
Funding Details:
The Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately $10.5 million (M) to fund approximately 1 Clinical Consortium Award – Coordinating Center application with a total cost cap of $10.5M. The maximum period of performance is 4 years. The CDMRP expects to allot approximately $22.0M to fund approximately 11 Clinical Consortium – Clinical Research Site applications with total cost caps of $2.0M. The maximum period of performance is 4 years. It is anticipated that awards made from this FY25 funding opportunity will be funded with FY25 funds, which will expire for use on September 30, 2031. Awards supported with FY25 funds will be made no later than September 30, 2026.
CDMRP intentionally funds innovative, paradigm‑shifting research across the full pipeline—from basic discovery to clinical trials—that addresses critical gaps in health outcomes for service members and the public .
Team‑science mechanisms (e.g., Synergistic Idea Awards) require multiple PIs—each funded independently—not sub-awards, encouraging true synergy across disciplines and institutions .
Tier 1: Peer review assesses technical merit.
Tier 2: Programmatic review weighs scientific excellence alongside program relevance, portfolio balance, and consumer advocate perspectives—consumers have equal voting power .
CDMRP includes nested awards for predoctoral, postdoctoral, and clinician-scientist candidates, with programs like the Ovarian Cancer Academy offering mentoring, networking, and skill-building .
Each program is guided by yearly appropriations and congressional mandate. Success depends on tightly aligning proposals with specific program objectives and anticipated topics .
RFAs are brief and often come with 30–60 days lead time. Staying alert to pre-announcements, registering in eBRAP and Grants.gov, and planning early are essential .
CDMRP actively coordinates with NIH and VA to prevent redundant funding. Before submitting, check existing programs and anticipate strategic adjustments to your proposal if overlap is flagged .
Core Factor | Why It Matters |
---|---|
Bold, high‑impact science | CDMRP rewards innovation and high risk |
Team/consortia readiness | Mechanisms favor multi‑PI, multi-institution studies |
Consumer inclusion | Proposals must speak to patient relevance and include advocates |
Mentoring and training plan | Especially for early- and mid-career awards |
Strict alignment with program scope | Tailor aims to each RFA and congressional intent |
Rapid response capability | Be ready to mobilize within 1–2 months |
Portfolio awareness & distinctiveness | Show how your proposal complements—not duplicates—other programs |
Track pre-announcements—sign up for CDMRP alerts and maintain your eBRAP profile.
Review recent funded summaries—understand what CDMRP programs value and shape your proposal accordingly.
Plan and build consortia early—ensure collaborators are involved from concept development to submission.
Engage consumer advocates—integrate patient or stakeholder perspectives in your aims and review process.
Check overlap and coordinate—avoid redundancy with NIH/VA programs; emphasize unique CDMRP-relevant aspects.
Prepare for fast turnarounds—have draft aims, compliant budgets, and institutional approvals ready to go.
Leverage nested training/career awards—if eligible, use them to build capacity and complement your full proposal.
🔧 Final Thought
CDMRP funding favors bold, multidisciplinary teams tackling high-priority challenges with consumer engagement, aligned to congressional mandates, and ready for rapid deployment. Proposals that demonstrate these qualities—and address career development—are strongly positioned to win.
Organization Extramural and intramural organizations are eligible to apply, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.
Extramural Organization: An eligible non-Department of Defense (DOD) organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organizations other than the DOD (i.e., intragovernmental organizations), and research institutes.
Intramural DOD Organization: Refers specifically to DOD organizations including DOD laboratories, DOD military treatment facilities, and/or DOD activities embedded within a civilian medical center.
Principal Investigator
Independent investigators with a faculty-level appointment (or equivalent) may be named as a Principal Investigator (PI). Individuals affiliated with an eligible organization are eligible to be named as PI regardless of ethnicity, nationality, or citizenship status.
Sponsor Institute/Organizations: Congressionally Directed Medical Research Programs
Sponsor Type: Corporate/Non-Profit
Address: 1077 Patchel Street Fort Detrick, MD 21702-5024 Phone: (301) 619-7071
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Aug 08, 2025
Aug 29, 2025
$10,500,000
Affiliation: Congressionally Directed Medical Research Programs
Address: 1077 Patchel Street Fort Detrick, MD 21702-5024 Phone: (301) 619-7071
Website URL: https://cdmrp.health.mil/funding/pa/HT942525PCRPCCA_GG%20v2.pdf
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.